A summary of survey results from ISPOR’s Annual North America meeting, where we gathered insights on important developments in the real world research space, including the impact of the 21st Century Cures Act on our industry.
Exploring Real-World Outcomes
THE INSIGHT SERIES: Why do prescribers participate? - Part III
While Phase II-III studies include small datasets, comprising several hundred to several thousand patients, they provide the data necessary for drug…
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…